临床试验总结报告英文版资料下载.pdf
- 文档编号:16119713
- 上传时间:2022-11-20
- 格式:PDF
- 页数:66
- 大小:184.51KB
临床试验总结报告英文版资料下载.pdf
《临床试验总结报告英文版资料下载.pdf》由会员分享,可在线阅读,更多相关《临床试验总结报告英文版资料下载.pdf(66页珍藏版)》请在冰豆网上搜索。
Reviewer:
@#@CynthiaA.Rask,M.D.Through:
@#@MarcK.Walton,M.D.,Ph.D.KarenWeiss,M.D.Date:
@#@23January2002BiologicsLicenseApplicationSupplementMedicalOfficersReviewRebif(Interferon-1a)FORTREATMENTOFRELAPSING-REMITTINGMULTIPLESCLEROSISSubmittedbySerono,Inc.STN#:
@#@103780/0RebifBLA(STN#103780/0)Serono,Inc.Page2of66TABLEOFCONTENTSOVERVIEW.4Scopeofthisreview.4AbbreviationsandDefinitionsofTermsUsedinThisReview.5INTRODUCTION.7MultipleSclerosis.7BackgroundandDiagnosticCriteria.7CurrentTreatmentofMS.8TheOrphanDrugActandOrphanDrugExclusivityRegulations.8OverviewofPriorClinicalStudiesofRebif.10PROTOCOLXXXXXXXXXX.12Objectives.12Design.12MaterialSource.13Randomization.14InclusionCriteria.14ExclusionCriteria.14Treatment.15EvaluationsPerformedDuringtheStudy.17EfficacyEndpoints.21PrimaryEndpoint.21SecondaryEndpoints.21TertiaryEndpoints.21SafetyEndpoints.21SafetyMeasurementsAnalyzed.21StatisticalAnalysisPlan.22DeterminationofSampleSize.22AnalysisPopulations.22PlannedInterimAnalysis.23SignificanceTesting,AllocationofAlpha.23AnalysisofBaselineParameters.23PrimaryEndpointProportionofSubjectsExacerbation-Freeat24Weeks.24RebifBLA(STN#103780/0)Serono,Inc.Page3of66SecondaryEndpointsMRIAnalyticMethods.24SafetyAnalyses.26StudyAdministration.26STUDYRESULTS.27FormalProtocolModifications.27ChangesintheConductoftheStudyorPlannedAnalyses.27ProtocolDeviations/Violations.28StudyConductatSpecificStudySites.30SubjectEnrollmentandDisposition.31Randomization.31TimeonStudy.31TimeonTreatment:
@#@.32AdverseEventsLeadingtoPrematureDiscontinuation.33DemographicsandBaselineCharacteristics.35EFFICACYRESULTS.38PrimaryEndpointResults.38CBER-PerformedAnalysesonthePrimaryEndpoint.42SecondaryEndpoints.48MRI-DeterminedCUActivity.48ExacerbationRateperSubject.49MeanNumberofT2ActiveLesionsperSubjectperScan.50TertiaryEndpoints.51ExploratoryAnalyses.53SafetyAnalyses.55SeriousAdverseEventsandDeaths.55ImportantRareSeriousAdverseEvents.58SevereAdverseEvents.59AnalysisbyBodySystemandEvent.60Pregnancies.62DevelopmentofAntibodiestoInterferon-.62AssessmentandConclusions.63FinancialDisclosureStatements.65References.65RebifBLA(STN#103780/0)Serono,Inc.Page4of66OverviewInterferon-1a(Rebif)hasbeenunderdevelopmentbySerono,Inc.forthetreatmentofmultiplesclerosis(MS).Serono,Inc.submittedaBiologicsLicenseApplication(BLA)onFebruary27,1998fortheapprovalofRebifforthetreatmentofpatientswithrelapsing-remittingMS(RRMS).Thefocusoftheapplicationwasa560-subjectstudythatwasarandomized,double-blind,placebo-controlledstudyof22gvs.44gRebifvs.placeboadministeredsubcutaneously(SC)threetimesperweekfor2years.Theapplicationalsocontainedadditionalopen-labelsafetydatafromotherstudies.BasedonthereviewoftheBLAsubmissionconductedbyCBER,itwasconcludedthatbothdosesofRebifweredemonstratedtobesafeandeffectiveandtobeapprovablefortreatmentofRRMS.However,SeronowaspreventedfrommarketingRebifintheUnitedStatesbytheOrphanDrugExclusivitypreviouslygrantedtoBiogenforthemarketingoftheirinterferon-1a,AvonexandtoBerlex/Chironforthemarketingoftheirinterferon-1b,BetaseronBetaseronsexclusivityexpiredinJuly2000.Rebifwas,however,successfullyapprovedandmarketedinothercountries,andthushasbeencommerciallyavailableinotherportionsoftheworldforseveralyears.ThesubjectofthecurrentBLAamendmentisacomparativestudythatSeronoconductedtocomparetheefficacyofRebiftomarketeddosesofAvonexinthetreatmentofrelapsing-remittingMS.ThestudydesignwasdiscussedwithCBERandthedesignwasagreeduponpriortoinitiationofthestudy.Thestudywasarandomized,open-labelstudyinwhichsubjectswithRRMSweretreatedwitheitherRebif44gSCthreetimesperweekorAvonex30gIMonceweekly,withneurologicexaminationsperformedbyphysiciansblindedtothetreatmentassignmentandwithsubjectsMRIsreadatacentralreadingfacilitybyneuroradiologistsblindedtotreatmentassignment.Althoughthedurationofthestudywastobe48weeks,thepre-specifiedprimaryoutcomemeasurewastheproportionofsubjectswhoremainedrelapse-freefollowing24weeksoftreatment.Supportiveevidence(secondaryendpoints)werecomparisonsofMRIabnormalities.TheApplicantconductedandsubmittedthisBLAamendmentinthebeliefthatdemonstrationofsuperiorclinicalbenefitofRebifoverAvonexwouldallowthemtobreakBiogensorphandrugexclusivityandthus,tomarketRebifintheU.S.forthetreatmentofrelapsing-remittingMS.ScopeofthisreviewThefocusofthisdocumentisuponefficacyinformationobtainedprimarilyfromasinglestudy,XXXXXXXXXX,arandomized,open-labelcomparativestudyoftheuseofRebif44gadministeredS
- 配套讲稿:
如PPT文件的首页显示word图标,表示该PPT已包含配套word讲稿。双击word图标可打开word文档。
- 特殊限制:
部分文档作品中含有的国旗、国徽等图片,仅作为作品整体效果示例展示,禁止商用。设计者仅对作品中独创性部分享有著作权。
- 关 键 词:
- 临床试验 总结报告 英文 精品 文档